BK virus nephropathy and kidney transplantation

Daniel L. Bohl, Daniel C. Brennan

Research output: Contribution to journalArticlepeer-review

Abstract

Nephropathy from BK virus (BKV) infection is an evolving challenge in kidney transplant recipients. It is the consequence of modern potent immunosuppression aimed at reducing acute rejection and improving allograft survival. Untreated BKV infections lead to kidney allograft dysfunction or loss. Decreased immunosuppression is the principle treatment but predisposes to acute and chronic rejection. Screening protocols for early detection and prevention of symptomatic BKV nephropathy have improved outcomes. Although no approved antiviral drug is available, leflunomide, cidofovir, quinolones, and intravenous Ig have been used. Retransplantation after BKV nephropathy has been successful.

Original languageEnglish (US)
Pages (from-to)S36-S46
JournalClinical Journal of the American Society of Nephrology
Volume2
Issue numberSUPPL. 1
DOIs
StatePublished - Jul 2007
Externally publishedYes

ASJC Scopus subject areas

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Fingerprint Dive into the research topics of 'BK virus nephropathy and kidney transplantation'. Together they form a unique fingerprint.

Cite this